We announced today that the FDA has approved the supplemental Biologics License Application (sBLA) for Spikevax® (2024-2025 formula) for individuals 12 years and above. Emergency Use Authorization (EUA) for Moderna’s COVID-19 Vaccine (2024-2025 formula) was also granted for

We announced today that we have received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation of our COVID-19 mRNA vaccine targeting the SARS-CoV-2 variant JN.1. Read more: investors.modernatx.com/news/news-deta…

We announced today that the European Commission has granted marketing authorization for our mRNA respiratory syncytial virus (RSV) vaccine. The marketing authorization follows the Positive Opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for

Vaccines play a vital role in public health. Data from the World Health Organization (WHO) show that vaccines prevent an estimated 3.5 to 5 million deaths each year from 20 different diseases. This National Immunization Awareness Month, read more about the vaccines you need to protect yourself this fall,

We announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized our updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2. Following the MHRA decision, doses will be available for eligible groups as part of the NHS autumn

We are likely to encounter the #COVID19 virus again as we enter another respiratory virus season, and the gravity of your next COVID-19 episode depends on a variety of factors.

Here are key things to keep in mind about repeat COVID infections as we approach the fall and winter months ⬇ usatoday.com/story/news/hea…

We announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of our COVID-19 mRNA vaccine, targeting the SARS-CoV-2 variant JN.1. Learn more:

We announced today that our manufacturing facility in Laval, Quebec, has been granted a Drug Establishment License (DEL) from Health Canada. This certification affirms the facility’s compliance with rigorous safety and quality standards, authorizing it to produce drug substance.